156 related articles for article (PubMed ID: 23018531)
1. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R; Wang JS; Castaneda L; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Tong G
Clin Pharmacokinet; 2012 Oct; 51(10):681-93. PubMed ID: 23018531
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens RC
Clin Ther; 2012 Mar; 34(3):654-67. PubMed ID: 22381714
[TBL] [Abstract][Full Text] [Related]
3. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G; Castaneda L; Wang JS; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright C; Dockens RC
Clin Drug Investig; 2012 Nov; 32(11):761-9. PubMed ID: 23018285
[TBL] [Abstract][Full Text] [Related]
4. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens R
Br J Clin Pharmacol; 2013 Jan; 75(1):136-45. PubMed ID: 22616739
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
6. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V; Salloway S; van Dyck CH; Dubois B; Andreasen N; Brody M; Curtis C; Soininen H; Thein S; Shiovitz T; Pilcher G; Ferris S; Colby S; Kerselaers W; Dockens R; Soares H; Kaplita S; Luo F; Pachai C; Bracoud L; Mintun M; Grill JD; Marek K; Seibyl J; Cedarbaum JM; Albright C; Feldman HH; Berman RM
JAMA Neurol; 2015 Nov; 72(11):1324-33. PubMed ID: 26414022
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.
Chandra KP; Shiwalkar A; Kotecha J; Thakkar P; Srivastava A; Chauthaiwale V; Sharma SK; Cross MR; Dutt C
Clin Drug Investig; 2009; 29(9):559-75. PubMed ID: 19663519
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ; Sanderson TP; Pilcher GD; Graziano MJ
Toxicol Sci; 2018 Jun; 163(2):525-542. PubMed ID: 29529279
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
13. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
17. BMS-708,163 targets presenilin and lacks notch-sparing activity.
Crump CJ; Castro SV; Wang F; Pozdnyakov N; Ballard TE; Sisodia SS; Bales KR; Johnson DS; Li YM
Biochemistry; 2012 Sep; 51(37):7209-11. PubMed ID: 22931393
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
20. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.
Sivaraman L; Sanderson T
Toxicol Appl Pharmacol; 2023 Jun; 469():116512. PubMed ID: 37030625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
